AbsEn.i
Analysis
2020
Racine
Analysis
2020
Exploration
Accueil
Racine
Racine

Serveur d'exploration Tocilizumab - Analysis (2020)

Index « AbsEn.i » - entrée « immunotherapy »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
immunotherapies < immunotherapy < immunsuppressiven  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 17.
Ident.Authors (with country if any)Title
000008 (2020) J. Prinz [Allemagne] ; Y. D'Hargues [Allemagne] ; P. Gödel [Allemagne] ; A. Shimabukuro-Vornhagen [Allemagne] ; M. Kochanek [Allemagne] ; B. Böll [Allemagne][CARs, CRS and neurotoxicity: severe complications after administration of immunotherapy : Essentials for intensivists].
000010 (2020) Aline Pfefferle [Australie] ; Nicholas D. Huntington [Australie]You Have Got a Fast CAR: Chimeric Antigen Receptor NK Cells in Cancer Therapy
000087 (2020) Wanhai Ke ; Li Zhang ; Yan DaiThe role of IL‐6 in immunotherapy of non‐small cell lung cancer (NSCLC) with immune‐related adverse events (irAEs)
000090 (2020) Muneyoshi Futami [Japon] ; Keisuke Suzuki [Japon] ; Satomi Kato [Japon] ; Saori Ohmae [Japon] ; Yoshio Tahara [Japon] ; Masanori Nojima [Japon] ; Yoichi Imai [Japon] ; Takayuki Mimura [Japon] ; Yoshihiro Watanabe [Japon] ; Arinobu Tojo [Japon]The novel multi-cytokine inhibitor TO-207 specifically inhibits pro-inflammatory cytokine secretion in monocytes without affecting the killing ability of CAR T cells.
000106 (2020) Akram Aminjafari [Iran] ; Sorayya Ghasemi [Iran]The Possible of Immunotherapy for COVID-19: a Systematic Review
000167 (2020) Peter A. Riedell ; Michael R. BishopSafety and efficacy of axicabtagene ciloleucel in refractory large B-cell lymphomas
000240 (2020) James Kalmuk [États-Unis] ; Jon Puchalla [États-Unis] ; Gong Feng [États-Unis] ; Anshu Giri [États-Unis] ; John Kaczmar [États-Unis]Pembrolizumab-induced Hemophagocytic Lymphohistiocytosis: an immunotherapeutic challenge
000268 (2020) Muhammad Khan [République populaire de Chine] ; Sumbal Arooj [Pakistan] ; Hua Wang [République populaire de Chine]NK Cell-Based Immune Checkpoint Inhibition
000287 (2020) Tania Jain ; Mark R. LitzowManagement of toxicities associated with novel immunotherapy agents in acute lymphoblastic leukemia
000306 (2020) Grant Broussard [États-Unis] ; Blossom Damania [États-Unis]KSHV: Immune Modulation and Immunotherapy
000342 (2020) Cinnie Yentia Soekojo ; Melissa Ooi ; Sanjay De Mel ; Wee Joo ChngImmunotherapy in Multiple Myeloma
000454 (2020) He Huang [République populaire de Chine] ; Heng-Wei Wu [République populaire de Chine] ; Yong-Xian Hu [République populaire de Chine]Current advances in chimeric antigen receptor T-cell therapy for refractory/relapsed multiple myeloma
000455 (2020) Hao Wang [République populaire de Chine] ; Zheng Xiao [République populaire de Chine]Current Progress on Assessing the Prognosis for Anti-N-Methyl-D-Aspartate Receptor (NMDAR) Encephalitis
000509 (2020) Gils Roex ; Tom Feys ; Yves Beguin ; Tessa Kerre ; Xavier Poiré ; Philippe Lewalle ; Peter Vandenberghe ; Dominique Bron ; Sébastien Anguille [Belgique]Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data
000510 (2020) Daniel Sur ; Andrei Havasi ; Calin Cainap ; Gabriel Samasca ; Claudia Burz ; Ovidiu Balacescu [Roumanie] ; Iulia Lupan [Roumanie] ; Diana Deleanu ; Alexandru Irimie [Roumanie]Chimeric Antigen Receptor T-Cell Therapy for Colorectal Cancer
000558 (2020) Jerry B. Harvey [États-Unis] ; Luan H. Phan [États-Unis] ; Oscar E. Villarreal [États-Unis] ; Jessica L. Bowser [États-Unis]CD73's Potential as an Immunotherapy Target in Gastrointestinal Cancers
000593 (2020) Jingyu Wang [République populaire de Chine] ; Fang Shen [République populaire de Chine] ; Ying Yao [République populaire de Chine] ; Lin-Lin Wang [République populaire de Chine] ; Yongjian Zhu [République populaire de Chine] ; Jue Hu [République populaire de Chine]Adoptive Cell Therapy: A Novel and Potential Immunotherapy for Glioblastoma

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/2020/Analysis

HfdIndexSelect -h $EXPLOR_AREA/Data/2020/Analysis/AbsEn.i -k "immunotherapy" 

HfdIndexSelect -h $EXPLOR_AREA/Data/2020/Analysis/AbsEn.i  \
                -Sk "immunotherapy" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/2020/Analysis/biblio.hfd

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    2020
   |étape=   Analysis
   |type=    indexItem
   |index=    AbsEn.i
   |clé=    immunotherapy
}}
Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021